Janux Therapeutics Inc JANX:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 5:50 PM EDT
19.50quote price arrow down-0.18 (-0.91%)
Volume
607
Close
19.68quote price arrow up+1.02 (+5.47%)
Volume
128,522
52 week range
16.32 - 37.99

...

Loading . . .
  • Open17.06
  • Day High19.70
  • Day Low17.06
  • Prev Close18.66
  • 52 Week High37.99
  • 52 Week High Date06/11/21
  • 52 Week Low16.32
  • 52 Week Low Date06/15/21

Key Stats

  • Market Cap781.49M
  • Shares Out39.71M
  • 10 Day Average Volume0.00M
  • Dividend-
  • Dividend Yield-
  • Beta
  • YTD % Change-

KEY STATS

  • Open17.06
  • Day High19.70
  • Day Low17.06
  • Prev Close18.66
  • 52 Week High37.99
  • 52 Week High Date06/11/21
  • 52 Week Low16.32
  • 52 Week Low Date06/15/21
  • Market Cap781.49M
  • Shares Out39.71M
  • 10 Day Average Volume0.00M
  • Dividend-
  • Dividend Yield-
  • Beta
  • YTD % Change-

RATIOS/PROFITABILITY

  • EPS (TTM)-0.19
  • P/E (TTM)-102.55
  • Fwd P/E (NTM)-
  • EBITDA (MRQ)-6.281M
  • ROE (MRQ)-
  • Revenue (MRQ)380,000.00
  • Gross Margin (MRQ)-
  • Net Margin (MRQ)-2,014.47%
  • Debt To Equity (MRQ)0.00%

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Janux Therapeutics Inc

There is no recent news for this security.

Latest From Our Partners

There is no recent news for this security.

Profile

MORE
Janux Therapeutics, Inc. is a biopharmaceutical company. The Company is engaged in developing therapeutics based on its Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. Its focus is on developing a class of T cell engagers (TCEs). It is developing a broad pipeline with programs targeting prostate-specific membrane antigen (PSMA), epidermal growth factor receptor (EGFR), and trophoblast cell surface antigen 2 (TROP2). Its...
David Campbell Ph.D.
President
Address
11099 TORREY PINES PARK ROAD
San Diego, CA
92037
United States